55
Participants
Start Date
June 3, 2015
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Rhenium Liposome Treatment
At the time of stereotactic biopsy a catheter will be placed within the tumor using stereotactic guidance. Once the patient has adequately recovered from the procedure as determined by the neurosurgeon, 186RNL will be infused through the CED catheter at the predetermined dose. Spectroscopic imaging will then be obtained at predefined time points to visualize the distribution of the 186RNL as well as calculated the actual dose retained within the tumor. Patients will be monitored longitudinally for evidence of toxicity and response by MRI.
RECRUITING
Northshore University Hospital, Manhasset
RECRUITING
UT Southwestern Medical Center, Dallas
RECRUITING
The Cancer Therapy and Research Center at UTHSCSA, San Antonio
Lead Sponsor
National Cancer Institute (NCI)
NIH
Plus Therapeutics
INDUSTRY